Angioedème héréditaire de type III : Questions médicales fréquentes
Nom anglais: Hereditary Angioedema Type III
Descriptor UI:D056828
Tree Number:C20.543.480.904.066.500.500
Termes MeSH sélectionnés :
Angiotensin II Type 2 Receptor Blockers
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Angioedème héréditaire de type III : Questions médicales les plus fréquentes",
"headline": "Angioedème héréditaire de type III : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Angioedème héréditaire de type III : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-20",
"dateModified": "2025-02-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Angioedème héréditaire de type III"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Angioedème",
"url": "https://questionsmedicales.fr/mesh/D000799",
"about": {
"@type": "MedicalCondition",
"name": "Angioedème",
"code": {
"@type": "MedicalCode",
"code": "D000799",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C20.543.480.904.066"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Angioedème héréditaire de type III",
"alternateName": "Hereditary Angioedema Type III",
"code": {
"@type": "MedicalCode",
"code": "D056828",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Timothy Craig",
"url": "https://questionsmedicales.fr/author/Timothy%20Craig",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam (L.M.F., D.M.C.); the Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla (M.A.R.), Ionis Pharmaceuticals, Carlsbad (L.B., V.J.A., K.B.N., A.R., B.F.B., C.N., A.R.M., E.S.), and the Division of Allergy, Immunology, and Rheumatology, University of California, Los Angeles, Los Angeles (R.T.) - all in California; the Department of Internal Medicine, Division of Immunology-Allergy Section and the Bernstein Clinical Research Center, University of Cincinnati College of Medicine, Cincinnati (J.A.B.); the Midwest Immunology Clinic, Plymouth, MN (J.R.); the Department of Medicine and Pediatrics, Penn State Health Allergy, Asthma, and Immunology, Hershey, PA (T.C.); Asthma and Allergy Research Associates, Dallas (W.R.L.); and Medical Research of Arizona, Scottsdale (M.E.M.)."
}
},
{
"@type": "Person",
"name": "Danny M Cohn",
"url": "https://questionsmedicales.fr/author/Danny%20M%20Cohn",
"affiliation": {
"@type": "Organization",
"name": "Amsterdam UMC, University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands."
}
},
{
"@type": "Person",
"name": "Marc A Riedl",
"url": "https://questionsmedicales.fr/author/Marc%20A%20Riedl",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam (L.M.F., D.M.C.); the Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla (M.A.R.), Ionis Pharmaceuticals, Carlsbad (L.B., V.J.A., K.B.N., A.R., B.F.B., C.N., A.R.M., E.S.), and the Division of Allergy, Immunology, and Rheumatology, University of California, Los Angeles, Los Angeles (R.T.) - all in California; the Department of Internal Medicine, Division of Immunology-Allergy Section and the Bernstein Clinical Research Center, University of Cincinnati College of Medicine, Cincinnati (J.A.B.); the Midwest Immunology Clinic, Plymouth, MN (J.R.); the Department of Medicine and Pediatrics, Penn State Health Allergy, Asthma, and Immunology, Hershey, PA (T.C.); Asthma and Allergy Research Associates, Dallas (W.R.L.); and Medical Research of Arizona, Scottsdale (M.E.M.)."
}
},
{
"@type": "Person",
"name": "Konrad Bork",
"url": "https://questionsmedicales.fr/author/Konrad%20Bork",
"affiliation": {
"@type": "Organization",
"name": "Hautklinik, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland."
}
},
{
"@type": "Person",
"name": "Yuxiang Zhi",
"url": "https://questionsmedicales.fr/author/Yuxiang%20Zhi",
"affiliation": {
"@type": "Organization",
"name": "Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus-a choice determined by metabolic phenotype.",
"datePublished": "2022-06-20",
"url": "https://questionsmedicales.fr/article/35723859",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40520-022-02142-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Echocardiographic Association of Epicardial Adipose Tissue with Ascending Aorta Elasticity in Patients with Type 2 Diabetes Mellitus.",
"datePublished": "2022-06-16",
"url": "https://questionsmedicales.fr/article/35710356",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/00033197221098298"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Relationships Between Glycated Hemoglobin and Bone Turnover Markers in Patients with Type 2 Diabetes but No Diabetic Nephropathy.",
"datePublished": "2022-06-09",
"url": "https://questionsmedicales.fr/article/35712058",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2147/IJGM.S366725"
}
},
{
"@type": "ScholarlyArticle",
"name": "Defining pathogenicity of NOTCH2 variants for diagnosis of Alagille syndrome type 2 using a large cohort of patients.",
"datePublished": "2022-05-23",
"url": "https://questionsmedicales.fr/article/35567760",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/liv.15292"
}
},
{
"@type": "ScholarlyArticle",
"name": "Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study.",
"datePublished": "2022-05-23",
"url": "https://questionsmedicales.fr/article/35607776",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/mds.29045"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système immunitaire",
"item": "https://questionsmedicales.fr/mesh/D007154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hypersensibilité",
"item": "https://questionsmedicales.fr/mesh/D006967"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hypersensibilité immédiate",
"item": "https://questionsmedicales.fr/mesh/D006969"
},
{
"@type": "ListItem",
"position": 5,
"name": "Urticaire",
"item": "https://questionsmedicales.fr/mesh/D014581"
},
{
"@type": "ListItem",
"position": 6,
"name": "Angioedème",
"item": "https://questionsmedicales.fr/mesh/D000799"
},
{
"@type": "ListItem",
"position": 7,
"name": "Angioedème héréditaire de type III",
"item": "https://questionsmedicales.fr/mesh/D056828"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Angioedème héréditaire de type III - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Angioedème héréditaire de type III",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Angioedème héréditaire de type III",
"description": "Comment est diagnostiqué l'angioedème héréditaire de type III ?\nQuels tests sont utilisés pour confirmer le diagnostic ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nQuel rôle joue l'historique familial dans le diagnostic ?\nLes tests cutanés sont-ils utiles pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=998#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Angioedème héréditaire de type III",
"description": "Quels sont les symptômes typiques de l'angioedème héréditaire de type III ?\nLes épisodes d'angioédème sont-ils douloureux ?\nÀ quelle fréquence surviennent les épisodes ?\nLes symptômes peuvent-ils apparaître sans déclencheur ?\nLes symptômes affectent-ils la respiration ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=998#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Angioedème héréditaire de type III",
"description": "Comment prévenir les épisodes d'angioédème ?\nLes patients doivent-ils porter un bracelet médical ?\nL'éducation des patients est-elle importante ?\nLes vaccinations sont-elles recommandées ?\nLes patients doivent-ils éviter le stress ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=998#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Angioedème héréditaire de type III",
"description": "Quels traitements sont disponibles pour l'angioedème héréditaire de type III ?\nLes patients doivent-ils éviter certains aliments ?\nLes traitements préventifs sont-ils efficaces ?\nLes corticostéroïdes sont-ils utilisés en urgence ?\nY a-t-il des traitements expérimentaux disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=998#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Angioedème héréditaire de type III",
"description": "Quelles complications peuvent survenir avec l'angioédème héréditaire ?\nL'angioédème peut-il entraîner des hospitalisations ?\nLes complications sont-elles fréquentes ?\nLes complications peuvent-elles être évitées ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=998#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Angioedème héréditaire de type III",
"description": "Quels sont les facteurs de risque de l'angioédème héréditaire ?\nL'âge influence-t-il le risque d'angioédème ?\nLe sexe joue-t-il un rôle dans le risque ?\nLes antécédents médicaux augmentent-ils le risque ?\nLes facteurs environnementaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D056828?mesh_terms=Angiotensin+II+Type+2+Receptor+Blockers&page=998#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment est diagnostiqué l'angioedème héréditaire de type III ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'anamnèse, les antécédents familiaux et des tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de dosage des protéines C1 inhibiteur et des tests génétiques sont effectués."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être similaires à ceux d'autres formes d'angioedème."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'historique familial dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un historique familial positif est crucial pour suspecter un angioedème héréditaire."
}
},
{
"@type": "Question",
"name": "Les tests cutanés sont-ils utiles pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les tests cutanés ne sont pas efficaces pour diagnostiquer ce type d'angioédème."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes typiques de l'angioedème héréditaire de type III ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des gonflements soudains, souvent au visage, aux mains et aux pieds."
}
},
{
"@type": "Question",
"name": "Les épisodes d'angioédème sont-ils douloureux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les épisodes peuvent être inconfortables, mais ils ne sont généralement pas douloureux."
}
},
{
"@type": "Question",
"name": "À quelle fréquence surviennent les épisodes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fréquence varie, certains patients ayant des épisodes fréquents, d'autres moins."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils apparaître sans déclencheur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent survenir sans cause identifiable, ce qui complique le traitement."
}
},
{
"@type": "Question",
"name": "Les symptômes affectent-ils la respiration ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certains cas, le gonflement peut affecter la respiration, nécessitant une attention médicale."
}
},
{
"@type": "Question",
"name": "Comment prévenir les épisodes d'angioédème ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les déclencheurs connus et suivre un traitement préventif peut aider."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils porter un bracelet médical ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bracelet médical peut informer les secours en cas d'urgence liée à l'angioédème."
}
},
{
"@type": "Question",
"name": "L'éducation des patients est-elle importante ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur la maladie et ses déclencheurs est essentielle pour la gestion."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations sont recommandées, mais doivent être discutées avec un médecin."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter le stress ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut être un déclencheur, donc des techniques de gestion du stress sont utiles."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'angioedème héréditaire de type III ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments antihistaminiques et des corticostéroïdes."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains aliments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas d'aliments spécifiques à éviter, mais certains peuvent déclencher des épisodes."
}
},
{
"@type": "Question",
"name": "Les traitements préventifs sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements préventifs peuvent réduire la fréquence et la gravité des épisodes."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils utilisés en urgence ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent être administrés en cas d'épisodes sévères."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements expérimentaux, comme les inhibiteurs de bradykinine, sont en cours d'étude."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'angioédème héréditaire ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des obstructions respiratoires et des infections secondaires."
}
},
{
"@type": "Question",
"name": "L'angioédème peut-il entraîner des hospitalisations ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des épisodes graves peuvent nécessiter une hospitalisation pour traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications ne sont pas fréquentes mais peuvent survenir dans des cas sévères."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par une gestion appropriée de la maladie."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'angioédème héréditaire ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux et des mutations génétiques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'angioédème ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le risque peut augmenter avec l'âge, mais il est souvent présent dès l'enfance."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le sexe n'influence pas significativement le risque d'angioédème héréditaire."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents médicaux de maladies auto-immunes peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains facteurs environnementaux peuvent déclencher des épisodes, mais ne sont pas des risques directs."
}
}
]
}
]
}
Frailty is a newly emerging complication of diabetes in older people and increasingly recognised in national and international clinical guidelines. However, frailty remains less clearly defined and fr...
Epicardial adipose tissue (EAT) is an emerging cardiovascular risk factor located between the myocardium and visceral pericardium. In order to investigate the association between EAT and ascending aor...
To investigate the relationships between glycated hemoglobin (HbA1c) level and bone turnover markers (BTMs) in patients with type 2 diabetes mellitus (T2DM) but no diabetic nephropathy....
Patients with T2DM were recruited at Hebei General Hospital in China. The participants were allocated to three groups: an HbA1c <7% group, an HbA1c 7%-9% group, and an HbA1c ≥9% group. Their general c...
The ages of the HbA1c <7% group and the HbA1c 7%-9% group were significantly higher than that of the HbA1c ≥9% group (...
An increase in HbA1c is associated with gradual decreases in the circulating concentrations of 25OHD and OC....
Alagille syndrome (ALGS) type 2 caused by mutations in NOTCH2 has genotypic and phenotypic heterogeneity. Diagnosis in some atypical patients with isolated hepatic presentation could be missed....
Using 2087 patients with paediatric liver manifestations, NOTCH2 allele frequencies, in-silico prediction, protein domains and clinical features were analysed to define the pathogenicity of NOTCH2 var...
Among 2087 patients with paediatric liver manifestations, significantly more NOTCH2 variants were absent in gnomAD in patients with elevated γ-glutamyltransferase (GGT) (p = .041). Significantly more ...
When NOTCH2 variants are absent in gnomAD, null variants and missense variants which were predicted to be pathogenic by at least three in-silico tools could be considered pathogenic in patients with h...
Several pieces of evidence have shown the neurotrophic effect of erythropoietin (EPO) and its introduction in the therapeutic practice of neurological diseases. However, its usefulness in the treatmen...
The study aims to investigate the safety, tolerability, and clinical effects of a nasally administered recombinant EPO in SCA2 patients....
Thirty-four patients were enrolled in this double-blind, randomized, placebo-controlled, phase I-II clinical trial of the nasally administered human-recombinant EPO (NeuroEPO) for 6 months. The primar...
The 6-month changes in SCAFI score were slightly higher in the patients allocated to NeuroEPO treatment than placebo in spite of the important placebo effect observed for this parameter. However, sacc...
This study demonstrated the safety and tolerability of NeuroEPO in SCA2 patients after 6 months of treatments and suggested a small clinical effect of this drug on motor and cognitive abnormalities, b...
Prevalence of Type 2 diabetes mellitus (T2DM) is high among Māori and other Pacific Island peoples in New Zealand. Current health services to address T2DM largely take place in primary healthcare sett...
This qualitative study undertaken was underpinned by the Tangata Hourua research framework. Focus groups with dietitians, community health workers (CHWs) and KM took place in South Auckland, New Zeala...
Analysis of focus group meetings identified three main themes common across the groups: whakawhanaungatanga (actively building relationships), cultural safety (mana enhancing) and cultural alignment t...
Supporting community based, non-clinical workers to build meaningful and culturally safe relationships with Māori and Pacific people has potential to improve diabetes outcomes....
Background Clinical prediction models have been developed for hospitalization for heart failure in type 2 diabetes. However, a systematic evaluation of these models' performance, applicability, and cl...
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemic conditions. A higher risk of developing Parkinson's disease (PD) in patients with T2DM has become evident...
Adiponectin is a key protein produced in adipose tissue, with crucial involvement in multiple metabolic processes. Di-(2-ethylhexyl) phthalate (DEHP), one of the phthalate compounds used as a plastici...
This study examined the correlation between urine levels of DEHP metabolite, epigenetic marker 5mdC/dG, ACE gene phenotypes, and adiponectin levels in a sample of 699 individuals aged 12-30 from Taiwa...
Results showed a positive relationship between mono-2-ethylhexyl phthalate (MEHP) and 5mdC/dG, and a negative association between both MEHP and 5mdC/dG with adiponectin. The study found that the inver...
In this young Taiwanese population, our findings suggest that urine MEHP levels are negatively correlated with serum adiponectin levels, and epigenetic modifications may play a role in this associatio...
Numerous studies have reported an association between neutrophils and T2DM, although this relationship remains unclear. This study aims to investigate the interaction of neutrophils and a dietary inte...
A comprehensive analysis was conducted on the framework of the CORDIOPREV study, which included 462 patients without T2DM at the beginning of the study. They were randomly assigned to either a Mediter...
Kaplan-Meier curves showed that the lowest tertile of basal neutrophils was associated with a reduced likelihood of T2DM incidence when compared to the middle [HR=0.499 (95%CI, 0.287-0.866)] and the h...
These findings suggest that monitoring neutrophils can help prevent the development of T2DM, as a reduction in neutrophil counts could be associated with improved insulin sensitivity. Following a Medi...